WuXi XDC Cayman Inc
2268
Rang in aandelen
#1886
WuXi XDC Cayman Inc. operates as an investment holding company and a global... WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Aandeelprijs
$8.78
Marktkapitalisatie
$11.12B
Verandering (1 dag)
-9.52%
Verandering (1 jaar)
0.57%
Land
CN
Handel WuXi XDC Cayman Inc (2268)
Categorie
Healthcare
P/S-ratio voor WuXi XDC Cayman Inc (2268)
P/S-ratio op October 2026 TTM: 10.77
Volgens de meest recente financiële rapporten en aandelenkoers van WuXi XDC Cayman Inc is de huidige P/S-ratio (TTM) 10.77. Eind 2024 had het bedrijf een P/S-ratio van 8.51.
P/S-ratiohistoriek voor WuXi XDC Cayman Inc van 2020 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 10.77 | -11.24% |
| 2025 | 12.13 | 42.53% |
| 2024 | 8.51 | -42.82% |
| 2023 | 14.89 | -49.39% |
| 2022 | 29.42 | -65.94% |
| 2021 | 86.37 | -70.02% |
| 2020 | 288.11 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 5.37 | -50.10% |
US
|
|
| 6.29 | -41.56% |
US
|
|
| 21.02 | 95.24% |
US
|
|
| 6.53 | -39.37% |
CN
|
|
| 6.80 | -36.85% |
US
|
